| Identification | Back Directory | [Name]
ISORHYNCHOPHYLLINE | [CAS]
6859-01-4 | [Synonyms]
IsoRhy
SUCROSE(USP)(RG)
Isorhyncophylline
ISORHYNCHOPHYLLINE
7-Isorhyncophylline
7-Isorhynchophylline
Isorhynchophylline CRS
ISORHYNCHOPHYLLINE (P)
ISORHYNCHOPHYLLINE (RG)
Isorhynchophylline, 98%, from Uncaria rhynchophylla(Miq.)Miq. ex Havil.
(16E,20α)-16,17-Didehydro-17-methoxy-2-oxocorynoxan-16-carboxylic acid methyl ester
(7S,16E,20R)-16,17-Didehydro-17-methoxy-2-oxocorynoxan-16-carboxylic acid methyl ester
(aE,1'S,6'R,7'S,8'aS)-6'-Ethyl-1,2,2',3',6',7',8',8'a-octahydro-alpha-(methoxymethylene)-2-oxospiro[3H-indole-3,1'(5'H)-indolizine]-7'-acetic acid methyl ester
Spiro[3H-indole-3,1'(5'H)-indolizine]-7'-acetic acid, 6'-ethyl-1,2,2',3',6',7',8',8'a-octahydro-α-(methoxymethylene)-2-oxo-, methyl ester, (αE,1'S,6'R,7'S,8'aS)- | [Molecular Formula]
C22H28N2O4 | [MDL Number]
MFCD01745920 | [MOL File]
6859-01-4.mol | [Molecular Weight]
384.47 |
| Chemical Properties | Back Directory | [Melting point ]
114℃ | [Boiling point ]
560.8±50.0 °C(Predicted) | [density ]
1.23 | [solubility ]
DMSO : 100 mg/mL (260.10 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble) | [form ]
powder | [pka]
13.61±0.60(Predicted) | [color ]
White |
| Hazard Information | Back Directory | [Description]
This amorphous base has been isolated from Ourouparia rhyncophylla Mats. It
has [α]29Db + 8.3° and yields a crystalline perchlorate, m.p. 150°C (dec.). | [Chemical Properties]
White crystalline powder, soluble in chloroform, derived from Uncaria rhynchophylla. | [Uses]
Isorhynchophylline is an oxindole alkaloid which has been the main active ingredient of Uncaria rhynchophylla contributing to anti-depressant like behavior in subjects. | [Definition]
ChEBI: A natural product found in Uncaria macrophylla. | [in vivo]
Isorhynchophylline (20-40 mg/kg, i.g., daily, 8 weeks) ameliorates D-galactose (HY-N0210)-induced learning and memory deficits in mice, at least in part, by enhancing the antioxidant status and anti-inflammatory effects of brain tissue through inhibition of NFκB signaling[9].
Isorhynchophylline (50 μM, the first day of every week from the 5th to the 8th week after surgery) alleviates osteoarthritis in rat osteoarthritis models, with decreasing OARSI score and the reduction of joint space[7].
Isorhynchophylline (10-40 mg/kg, i.g., 7 days) exerts antidepressant-like effects in mice at least in part by inhibiting monoamine oxidase[10].
Isorhynchophylline (20-40 mg/kg, i.g., daily, 8 weeks) alleviates learning and memory impairments induced by aluminum chloride in mice[11].
Isorhynchophylline (20? mg/kg, i.p., 14 or 42 days) alleviates silicon-dioxide-induced lung injury in mice, with reducing inflammatory responses and fibrosis[12].
| Animal Model: | D-galactose-induced cognitive deficits (Ten-week-old male ICR mice received a daily subcutaneous injection of D-gal at a dose of 100 mg/kg for 8 weeks)[9] | | Dosage: | 20, 40 mg/kg | | Administration: | Given intragastrically (i.g.), daily, 8 weeks | | Result: | Shortened the mean latency to find the platform at the 4th day (20 mg/kg).
Led to a significant increase in the number of target crossings (40 mg/kg).
Attenuated oxidative stress (enhanced the level of GSH, attenuated MDA).
Decreased the production of NO and the mRNA expression of iNOS in the brain (40 mg/kg).
Decreased the production of PGE2 and the mRNA expression of COX-2 (40 mg/kg).
Suppressed the protein level of p-IκBα (40 mg/kg).
|
| [target]
Potassium Channel | [References]
Kondo, Fukuda, Tomita., J. Pharm. Soc., Japan, 48, 54 (1928)
Kondo, Ikeda., ibid, 57,237 (1937) |
|
|